ClinicalTrials.gg

Program

TD001

A development code.

Its studies are mostly in Prostatic Neoplasms, Castration-Resistant, led by T.O.A.D. Oncology.

Furthest: phase 2, since Nov 20, 20251 company-led study, 1 open or runningNext primary completion: Mar 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
T.O.A.D. Oncology11 open or runningphase 2since Nov 20, 2025Nov 20, 2025Mar 2028phase 2 · NCT07258407

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2025First study: phase 2 study in Prostatic Neoplasms, Castration-ResistantFirst studyNCT07258407 · 180 planned · United States, Australia, Canada and more

Ahead

  1. Mar 2028Primary completion: phase 2 study in Prostatic Neoplasms, Castration-ResistantNCT07258407

TargetBeta

FOLH1 →read by rule
“This study will evaluate the safety, tolerability, drug levels (pharmacokinetics) and preliminary antitumor activity of TD001, an antibody-drug conjugate (ADC) targeting prostate-specific membrane antigen (PSMA), in men with metastatic PSMA-expressing castration-resistant prostate cancer (CRPC).”study text, by rule · the study

Other programs on FOLH1

ProgramCompanyFurthest phaseStudies
flotufolastat F 18ruleBraccophase 47
piflufolastatruleLantheusphase 45
abefolastat tesaroxetan CU-64ruleclarity-pharmaceuticals-ltdphase 35
gallium 68 PSMA-11ruleNovartisphase 34
Lutetium Lu 177 Ludotadipeprulefuturechemphase 33
Anti-PSMA/Anti-CD28 Bispecific Antibody JNJ-87189401Johnson & Johnsonphase 32
Lutetium Lu 177 NYM032ruleNorroy Biosciencephase 32
actinium AC-225 vipivotide tetraxetanNovartisphase 32
HRS-4357Jiangsu HengRui Medicinephase 32
zadavotide guraxetanAstraZenecaphase 24
AB-001rulefrontier-biotechnologies-incphase 23
olsutamigruleRegeneron Pharmaceuticalsphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07258407Prostatic Neoplasms, Castration-Resistant · United States, Australia, Canada and more2RecruitingMar 2028180

How it is read

Names in the registry

  • “TD001”, 1 entry

Codes read as this program: TD001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.